Phase 3 Rare Disease Trial, Recruiting NCT07668856 Sponsor: UMC Utrecht Condition: Rare Disease
Back to Rare Disease

Phase 3 Rare Disease Trial, Recruiting

NCT07668856
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 1 and 18 years old
  • You have been officially diagnosed with epilepsy that has not responded well to treatment (known as refractory epilepsy), confirmed using recognised medical guidelines
  • You have had at least 4 seizures during a 4-week observation period before the trial starts, and these seizures did not all happen within the same week
  • All your epilepsy medications or other treatments have been at the same dose for at least one month before screening, and you and your doctor are willing to keep them the same throughout the trial
  • You (or your parent or legal guardian) are able to give informed consent to take part
  • There is a caregiver who is regularly available and able to report on your condition throughout the trial

Who may not be able to join:

  • You have a known or suspected allergy or sensitivity to cannabinoids (cannabis-based substances) or any ingredients in the trial medication, which contains cannabis extract and refined peanut oil (confirm with trial site if you have a peanut allergy)
  • You have a known history of, or current signs of, significant liver problems, including abnormal liver test results above certain levels
  • You are pregnant, breastfeeding, or planning to become pregnant during the trial or within 3 months of finishing treatment
  • You have a heart condition, including structural heart problems, heart failure, reduced blood supply to the heart, Brugada syndrome, long-QT syndrome, or irregular heart rhythms
  • You have glaucoma (a condition affecting pressure in the eyes)
  • You are currently being assessed to see whether you might be suitable for epilepsy surgery
  • You had a vagal nerve stimulator (a device used to reduce seizures) fitted within the last 3 months and are not willing to wait until its settings are stable before joining
  • You started a ketogenic diet (a special high-fat, low-carbohydrate diet sometimes used for epilepsy) within the last 3 months and are not willing to wait until the diet is stable before joining
  • You have another ongoing medical condition, separate from your epilepsy, that could significantly affect your ability to take part (your doctor will help decide this)
  • You have used recreational or medicinal cannabis, or any cannabis-based medication, within the last 3 months and are not willing to stop using it for the duration of the study
  • You are planning to have a procedure under general anaesthetic that would affect the observation period before the trial, or any major surgery during the trial
  • You are not expected to be able to have blood samples taken due to significant anxiety or resistance
  • You have been taking a specific anti-seizure medication called clobazam at a dose higher than 0.5 mg per kg of body weight per day during the last month

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 088 755 5555

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
UMC Utrecht
Registry
ClinicalTrials.gov
Start date
6 February 2025
Est. completion
1 November 2027

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Seizure frequency

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov